| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Medicine details |
|
| Medicine name | ixekizumab (Taltz®) |
| Formulation | 80 mg solution for injection |
| Reference number | 2051 |
| Indication | Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug therapies |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 28/12/2017 |
| NICE guidance | TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |